Balaxi Pharma

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE618N01022
NSEID: BALAXI
BSEID:

INR

34.10

-0.87 (-2.49%)

BSENSE

Dec 05

BSE+NSE Vol: 43831

{
  "main_header": {
    "sid": 999933,
    "name": "Balaxi Pharma",
    "stock_name": "Balaxi Pharma",
    "full_name": "Balaxi Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/balaxi-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "34.10",
    "chg": -0.87,
    "chgp": "-2.49%",
    "dir": -1,
    "prev_price": "34.97",
    "mcapval": "193.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "BALAXI",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 5,
    "indexname": "",
    "isin": "INE618N01022",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 43831,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/balaxi-pharma-999933-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Balaxi Pharma’s Evaluation Metrics Revised Amid Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharma-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3746426",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BalaxiPharma_mojoScore_3746426.png",
        "date": "2025-12-04 11:08:33",
        "description": "Balaxi Pharma has experienced a revision in its evaluation metrics, reflecting a more cautious market assessment. This shift is driven by changes across key analytical parameters including quality, valuation, financial trends, and technical outlook, signalling a complex environment for this pharmaceuticals and biotechnology microcap."
      },
      {
        "title": "Why is Balaxi Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-balaxi-pharma-fallingrising-3742471",
        "imagepath": "",
        "date": "2025-12-03 00:49:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Persistent Underperformance Against Market Benchmarks</strong></p>\n<p>Balaxi Pharma’s stock has consistently underperformed the broader market indices over multiple time horizons. Over the past week, the stock fell by 6.89%, contrasting sharply with the Sensex’s modest gain of 0.57%. The divergence widens over longer periods, with the stock declining 17.21% in the last month while the Sensex rose 1.21%. Year-to-date, Balaxi Pharma has plummeted 50.84%, whereas the Sensex has advanced 10.10%. The one-year and three-year returns further highlight this trend, with Balaxi Pharma posting losses of 56.30% and 69.41% respectively, compared to Sensex gains of 7.23% and 39.24%. Even over five years, the stock has lost 71.19%, starkly underperforming the Sensex’s 98.51% rise. This sustained underperfo..."
      },
      {
        "title": "Is Balaxi Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-balaxi-pharma-overvalued-or-undervalued-3709911",
        "imagepath": "",
        "date": "2025-11-18 08:24:26",
        "description": "As of 17 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 13.68, an EV to EBIT of 10.81, and a Price to Book Value of 0.83. These ratios suggest that Balaxi Pharma is trading at a discount compared to its earnings and book value, which is favorable for potential investors.\n\nIn comparison to its peers, Balaxi Pharma's valuation metrics are significantly more appealing. For instance, Bajaj Finance has a PE ratio of 34.85, while Life Insurance stands at 11.33, both of which highlight Balaxi's competitive positioning within the pharmaceuticals and biotechnology sector. Additionally, Balaxi's PEG ratio is notably low at 0.00, further reinforcing its undervaluation. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline..."
      },
      {
        "title": "Why is Balaxi Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-balaxi-pharma-fallingrising-3708431",
        "imagepath": "",
        "date": "2025-11-17 22:47:21",
        "description": "As of 17-Nov, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 35.92, which reflects a decrease of Rs. 1.51 or 4.03%. The stock has hit a new 52-week low of Rs. 35.67 today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has underperformed its sector by 4.45%, and its returns have been significantly negative, with a 1-year return of -53.75%. The company's financial performance has also been troubling, with a -56.1% decline in profits over the past year, and a weak long-term fundamental strength indicated by a -4.77% CAGR growth in operating profits. Additionally, institutional investors have reduced their stake by 5.37%, reflecting a lack of confidence in the stock.\n\nIn the broader market context, Balaxi Pharmaceuticals has underperformed the benchmark, with a 1-week return of -13.90% compared to the..."
      },
      {
        "title": "Is Balaxi Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-balaxi-pharma-overvalued-or-undervalued-3696162",
        "imagepath": "",
        "date": "2025-11-13 08:11:55",
        "description": "As of 12 November 2025, Balaxi Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.43, an EV to EBIT of 11.36, and an EV to EBITDA of 10.38. These ratios suggest that Balaxi Pharma is trading at a discount relative to its earnings potential.\n\nIn comparison to its peers, Balaxi Pharma's PE ratio is significantly lower than that of Bajaj Finance, which stands at 34.41, and also lower than Bajaj Finserv at 33.6. On the other hand, it is more favorable than Life Insurance, which has a PE of 11.14, indicating that while Balaxi is undervalued, it is still competitive within the industry. Notably, Balaxi Pharma's stock has underperformed against the Sensex, with a year-to-date return of -47.57% compared to the Sensex's 9.44%, reinforcing the notion of its current undervaluation...."
      },
      {
        "title": "Balaxi Pharmaceuticals Experiences Quality Grade Change Amid Mixed Financial Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-downgraded-to-below-average-quality-grade-amid-stock-decline-3696390",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BalaxiPharmaceu_qualitydot_3696390.png",
        "date": "2025-11-13 08:00:39",
        "description": "Balaxi Pharmaceuticals has experienced a revision in its evaluation, marked by a 15.04% sales growth over five years, despite a 4.77% decline in EBIT. With a low net debt to equity ratio of 0.11 and a 25.08% return on equity, the company faces competitive challenges in the market."
      },
      {
        "title": "How has been the historical performance of Balaxi Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-balaxi-pharma-3695375",
        "imagepath": "",
        "date": "2025-11-13 00:18:51",
        "description": "Answer:\nThe historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nBalaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 20..."
      },
      {
        "title": "How has been the historical performance of Balaxi Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-balaxi-pharma-3694691",
        "imagepath": "",
        "date": "2025-11-12 23:51:11",
        "description": "Answer:\nThe historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.\n\nBreakdown:\nBalaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down f..."
      },
      {
        "title": "Why is Balaxi Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-balaxi-pharma-fallingrising-3693544",
        "imagepath": "",
        "date": "2025-11-12 22:41:32",
        "description": "As of 12-Nov, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 37.91, which reflects a decrease of Rs. 2.06 or 5.15%. The stock has hit a new 52-week low today and has underperformed its sector by 5.84%. Additionally, it is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Over the past week, the stock has seen a significant drop of 11.40%, and its year-to-date performance shows a staggering decline of 47.57%. Despite a notable increase in delivery volume by 439.12% compared to the 5-day average, the overall sentiment appears negative, with no positive factors reported to counterbalance the stock's poor performance.\n\nIn the broader market context, Balaxi Pharmaceuticals' recent performance contrasts sharply with the Sensex, which has gained 1.09% over the past week and 9.44% year-to-date. This stark difference ..."
      }
    ],
    "total": 86,
    "sid": "999933",
    "stock_news_url": "https://www.marketsmojo.com/news/balaxi-pharmaceuticals-999933"
  },
  "announcements": [
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Resignation of Mr Nidhin Jose as Chief Financial Officer of the company w.e.f. November 30, 2019.",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Resignation",
      "datetime": "21-Nov-2019"
    },
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Statement of deviation(s) or variation(s) under Reg. 32 of SEBI (LODR) Regulations 2015",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Statement of deviation(s) or variation(s) under Reg. 32",
      "datetime": "30-Oct-2019"
    },
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Board meeting held on October 29, 2019.",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Outcome of Board Meeting",
      "datetime": "29-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Balaxi Pharmaceuticals Ltd has declared <strong>5%</strong> dividend, ex-date: 01 Jul 22",
          "dt": "2022-07-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Balaxi Pharmaceuticals Ltd has announced <strong>2:10</strong> stock split, ex-date: 30 May 24",
          "dt": "2024-05-30",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Balaxi Pharma’s Evaluation Metrics Revised Amid Challenging Market Conditions

2025-12-04 11:08:33

Balaxi Pharma has experienced a revision in its evaluation metrics, reflecting a more cautious market assessment. This shift is driven by changes across key analytical parameters including quality, valuation, financial trends, and technical outlook, signalling a complex environment for this pharmaceuticals and biotechnology microcap.

Why is Balaxi Pharma falling/rising?

2025-12-03 00:49:02

Persistent Underperformance Against Market Benchmarks

Balaxi Pharma’s stock has consistently underperformed the broader market indices over multiple time horizons. Over the past week, the stock fell by 6.89%, contrasting sharply with the Sensex’s modest gain of 0.57%. The divergence widens over longer periods, with the stock declining 17.21% in the last month while the Sensex rose 1.21%. Year-to-date, Balaxi Pharma has plummeted 50.84%, whereas the Sensex has advanced 10.10%. The one-year and three-year returns further highlight this trend, with Balaxi Pharma posting losses of 56.30% and 69.41% respectively, compared to Sensex gains of 7.23% and 39.24%. Even over five years, the stock has lost 71.19%, starkly underperforming the Sensex’s 98.51% rise. This sustained underperfo...

Is Balaxi Pharma overvalued or undervalued?

2025-11-18 08:24:26

As of 17 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 13.68, an EV to EBIT of 10.81, and a Price to Book Value of 0.83. These ratios suggest that Balaxi Pharma is trading at a discount compared to its earnings and book value, which is favorable for potential investors. In comparison to its peers, Balaxi Pharma's valuation metrics are significantly more appealing. For instance, Bajaj Finance has a PE ratio of 34.85, while Life Insurance stands at 11.33, both of which highlight Balaxi's competitive positioning within the pharmaceuticals and biotechnology sector. Additionally, Balaxi's PEG ratio is notably low at 0.00, further reinforcing its undervaluation. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline...

Why is Balaxi Pharma falling/rising?

2025-11-17 22:47:21

As of 17-Nov, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 35.92, which reflects a decrease of Rs. 1.51 or 4.03%. The stock has hit a new 52-week low of Rs. 35.67 today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has underperformed its sector by 4.45%, and its returns have been significantly negative, with a 1-year return of -53.75%. The company's financial performance has also been troubling, with a -56.1% decline in profits over the past year, and a weak long-term fundamental strength indicated by a -4.77% CAGR growth in operating profits. Additionally, institutional investors have reduced their stake by 5.37%, reflecting a lack of confidence in the stock. In the broader market context, Balaxi Pharmaceuticals has underperformed the benchmark, with a 1-week return of -13.90% compared to the...

Is Balaxi Pharma overvalued or undervalued?

2025-11-13 08:11:55

As of 12 November 2025, Balaxi Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.43, an EV to EBIT of 11.36, and an EV to EBITDA of 10.38. These ratios suggest that Balaxi Pharma is trading at a discount relative to its earnings potential. In comparison to its peers, Balaxi Pharma's PE ratio is significantly lower than that of Bajaj Finance, which stands at 34.41, and also lower than Bajaj Finserv at 33.6. On the other hand, it is more favorable than Life Insurance, which has a PE of 11.14, indicating that while Balaxi is undervalued, it is still competitive within the industry. Notably, Balaxi Pharma's stock has underperformed against the Sensex, with a year-to-date return of -47.57% compared to the Sensex's 9.44%, reinforcing the notion of its current undervaluation....

Balaxi Pharmaceuticals Experiences Quality Grade Change Amid Mixed Financial Performance

2025-11-13 08:00:39

Balaxi Pharmaceuticals has experienced a revision in its evaluation, marked by a 15.04% sales growth over five years, despite a 4.77% decline in EBIT. With a low net debt to equity ratio of 0.11 and a 25.08% return on equity, the company faces competitive challenges in the market.

How has been the historical performance of Balaxi Pharma?

2025-11-13 00:18:51

Answer: The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years. Breakdown: Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 20...

How has been the historical performance of Balaxi Pharma?

2025-11-12 23:51:11

Answer: The historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods. Breakdown: Balaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down f...

Why is Balaxi Pharma falling/rising?

2025-11-12 22:41:32

As of 12-Nov, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 37.91, which reflects a decrease of Rs. 2.06 or 5.15%. The stock has hit a new 52-week low today and has underperformed its sector by 5.84%. Additionally, it is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Over the past week, the stock has seen a significant drop of 11.40%, and its year-to-date performance shows a staggering decline of 47.57%. Despite a notable increase in delivery volume by 439.12% compared to the 5-day average, the overall sentiment appears negative, with no positive factors reported to counterbalance the stock's poor performance. In the broader market context, Balaxi Pharmaceuticals' recent performance contrasts sharply with the Sensex, which has gained 1.09% over the past week and 9.44% year-to-date. This stark difference ...

View All News

Announcement

Balaxi Ventures Limited - Resignation

21-Nov-2019 | Source : NSE

Balaxi Ventures Limited has informed the Exchange regarding Resignation of Mr Nidhin Jose as Chief Financial Officer of the company w.e.f. November 30, 2019.